CROI 2008: Boston, Massachussetts; February 3-6, 2008

Key Links:

By Topic:



CROI 2008: Index of Coverage

Conference Highlights

To hear or see many of the original important oral presentations, click here.

  • Joel Gallant, M.D.
    Joel Gallant, M.D.
    Dr. Joel Gallant, M.D., M.P.H., Johns Hopkins University School of Medicine, Baltimore, Md.
    A review of CROI 2008 specifically for HIV-positive people. If you want to get the lowdown on recent HIV research in non-doctor speak, this is the interview you should read (or listen to).

  • Keith Henry, M.D.
    Keith Henry, M.D.
    Keith Henry, M.D., University of Minnesota School of Medicine, Minneapolis, Minn.
    As the huge CROI 2008 conference drew to a close, we sat down with Dr. Keith Henry for an interview. What did he think were some of the highlights of the conference? Read this interview for one respected physician's perspective.

  • David Wohl, M.D.
    David Wohl, M.D.
    David Wohl, M.D., University of North Carolina-Chapel Hill, N.C.
    David Wohl, M.D., discusses what he thought was the highlight of CROI 2008: results from the failed STEP vaccine study, which indicate that the vaccine may have increased HIV infection rates only for uncircumcised men.

  • Robert Schooley, M.D., University of California, San Diego, Calif.
    Robert Schooley, M.D., discusses some study findings presented at CROI 2008 on immune-based therapies; the best time to start patients on HAART; HIV and aging; non-AIDS-related infections and malignancies; hepatitis C coinfection; and vaccine and microbicide research.

Antiretrovirals in Development

  • Barry Zingman, M.D.
    Barry Zingman, M.D.
    CCR5 Inhibitors in Development: New Data on SCH532706 and Vicriviroc

  • Targets for a New Generation of HIV Antiretrovirals
    Mario Stevenson, Ph.D., previews CROI 2008 studies on cellular cofactors.

Complications of HIV/HAART

  • David Wohl, M.D.
    David Wohl, M.D.
    Complications of HIV/HAART: A Summary of Key Research
    In this summary and accompanying slide set, David Wohl, M.D., delves into new research on the use of low-dose growth hormone to treat lipohypertrophy; the point at which fat loss becomes clinically evident; a potential role for chromium supplementation in lipoatrophy treatment; the association between abacavir (Ziagen) -- and, to a lesser extent, didanosine (ddI, Videx) -- and myocardial infarction risk; the impact of HIV, and HIV therapy, on inflammatory markers; and our evolving understanding of the interplay between aging and HIV.

  • Viral Clade May Impact HIV Disease Progression Rate Among Treatment-Naive Patients, Canadian Study Suggests
    In a study comparing CD4+ cell count change and HIV disease progression among French Canadians, African immigrants and Haitian immigrants in Montreal, Marina Klein, M.D., M.Sc., and Marina Keller, M.D., find evidence to suggest that HIV viral clade matters.

  • Lawrence Siegel, M.D., M.P.H.
    Lawrence Siegel, M.D., M.P.H.
    Growing Syphilis Epidemic Among HIV-Infected MSM in New York City
    Lawrence Siegel, M.D., discusses his study, which found high rates of syphilis infection among HIV-infected men who have sex with men in a racially diverse clinic in the New York City neighborhood of Chelsea.

  • Marta Boffito, M.D., Ph.D.
    Marta Boffito, M.D., Ph.D.
    Short-Term Ritonavir Exposure Impacts HDL, CD36 and Triglyceride Levels in Healthy Volunteers
    Marta Boffito, M.D., Ph.D., discusses her study, which examines the possible role of ritonavir in increasing cardiovascular risk.

  • Barbara da Silva, M.D.
    Barbara da Silva, M.D.
    Bone Loss Similar Among Patients Taking Lopinavir/Ritonavir or Efavirenz; Race, Baseline CD4 May Play Role
    Barbara da Silva, M.D., summarizes the findings of her study, in which patients taking lopinavir/ritonavir (LPV/r, Kaletra) and efavirenz (EFV, Sustiva, Stocrin) did not experience different levels of bone mineral density (BMD) loss. This was not altered by simplification to lopinavir/ritonavir monotherapy, which suggests that BMD loss occurs independently of the treatment regimen used.

  • Giovanni Guaraldi, M.D.
    Giovanni Guaraldi, M.D.
    Non-Alcoholic Fatty Liver Disease Is Common in HAART-Experienced Patients; Several HIV- and Antiretroviral-Related Factors May Play Role
    An interview with Giovanni Guaraldi, M.D.

  • Francisco Blanco, M.D., Ph.D.
    Francisco Blanco, M.D., Ph.D.
    Antiretroviral Exposure May Increase Liver Fibrosis Risk; Non-Invasive Tool Simplifies Fibrosis Assessment
    Francisco Blanco, M.D., Ph.D., summarizes his study, which utilized non-invasive FibroScan elastometry rather than biopsy to measure fibrosis in HIV monoinfected and HIV/hepatitis C-coinfected patients.

  • Richard Rutstein, M.D.
    Richard Rutstein, M.D.
    Vitamin D Deficiency More Common Among Perinatally HIV-Infected Children Than HIV-Uninfected Children
    Richard Rutstein, M.D., discusses the impact of HIV status, ethnicity, diet and season on likelihood of vitamin D deficiency in his study of perinatally infected children.

  • Jens Lundgren, M.D.
    Jens Lundgren, M.D.
    Abacavir, Didanosine Associated With Higher Heart Attack Risk, D:A:D Study Finds
    One of the most talked-about studies presented at CROI 2008, the new D:A:D findings focus on the impact of specific antiretrovirals on heart attack risk in HIV-infected patients. Jens Lundgren, M.D., Chief Physician and Director of the Copenhagen HIV Programme, summarizes the data and discusses the ramifications of the results.

  • Jonathan Shuter, M.D.
    Jonathan Shuter, M.D.
    Among Patients on Boosted-PI Regimens, Dose Staggering and Selective Non-Adherence to Ritonavir Is Relatively Common
    Gerald Pierone, M.D., interviews Jonathan Shuter, M.D., regarding his study on ritonavir (RTV, Norvir) non-adherence in patients receiving atazanavir (ATV, Reyataz) + ritonavir or fosamprenavir (FPV, Lexiva, Telzir).

  • HIV-Related Infections and Conditions (April 2008)
    In Project Inform Perspective, from Project Inform

  • Study Finds Heart Trouble With Ziagen and Videx (February 4, 2008)
    From Project Inform

  • Increased Risk of Myocardial Infarction Associated With Abacavir and ddI (February 4, 2008)
    From HIV i-Base

  • Position Statement by the D:A:D Steering Committee (February 4, 2008)
    To read PDF, click here
    From D:A:D Steering Committee

Elite HIV Controllers/Exposed Uninfected

  • Shiv Gandhi
    Shiv Gandhi
    APOBEC3G/F Mutation Not Responsible for HIV Viremia Control in Most Elite HIV Suppressors
    Shiv Gandhi discusses his study, which examined the potential role of the APOBEC3 protein in patients who are able to maintain full suppression of HIV viremia despite never taking antiretroviral therapy.

  • Peter Hunt, M.D.
    Peter Hunt, M.D.
    Elite Controllers May Experience Higher Immune Activation Levels Than Other HIV-Infected Patients, Spurring Concerns of CD4+ Decline
    In this interview with Gerald Pierone, M.D., Peter Hunt, M.D., discusses his study on the relationship between HIV-specific immune response, T-cell activation and CD4+ T-cell depletion in elite viremic controllers.

  • Richard Novak, M.D.
    Richard Novak, M.D.
    Presence of Binding Antibodies in Genital Secretions of High-Risk, HIV-Uninfected Women Offers Possible Explanation of "HIV Immunity" Enigma
    Richard Novak, M.D., speaks with Gerald Pierone, M.D., about his study of the potentially protective effect of genital mucosal secretions in high-risk HIV-uninfected women and its implications for vaccine development.

  • Hans-Jurgen Stellbrink, M.D.
    Hans-Jürgen Stellbrink, M.D.
    CD4+ Cell Count Declines Slowly, But Steadily, in Elite HIV Controllers, Small Study Finds
    Hans-Jürgen Stellbrink, M.D., speaks about his study, which finds an unmistakable (albeit gradual) downward trend in CD4+ cell count over time among a small cohort of patients with undetectable HIV viral load in the absence of HAART.

Gender and Racial Differences in HIV/HAART

  • Kathryn Anastos, M.D.
    Kathryn Anastos, M.D.
    Women and HIV -- Natural History, Prevention and Treatment: A Summary of Key Research
    In this summary and accompanying slide set, Kathryn Anastos, M.D., provides an in-depth discussion of our growing understanding of the differences between women and men in the realms of HIV pathogenesis and disease progression, antiretroviral therapy, complications and HIV prevention.

  • Diana Lemly, M.D.
    Diana Lemly, M.D.
    Mortality Higher Among HIV-Infected Black Patients; Women, Blacks Spend Less Time on HAART
    In this interview, Diana Lemly, M.D., discusses her study, which found disparities in antiretroviral use and survival comparing women with men, and African Americans with whites.

Hepatitis/HIV Coinfection

  • Study Examines Pro-Inflammatory Responses in HIV/HCV-Coinfected Injection Drug Users
    Camilla Graham, M.D., discusses her study examining immune response and pro-inflammatory marker activation in HIV/hepatitis C-coinfected heroin and methadone users.

  • Roksana Karim, M.D., Ph.D.
    Roksana Karim, M.D., Ph.D.
    Higher HCV RNA Levels Associated With Greater Early T-Cell Activation and CD4+ Cell Depletion Among Antiretroviral-Naive, HIV/HCV-Coinfected Patients
    Roksana Karim, M.D., Ph.D., discusses her study, which examines the impact of HIV/hepatitis C coinfection on immune activation-driven CD4+ decline in women who have not yet commenced HAART.

  • HIV/HCV-Coinfected Patients Appear More Likely Than HIV-Monoinfected Patients to Develop Insulin Resistance After Initiating HAART
    Cecilia Shikuma, M.D., reviews her study, which compares metabolic changes in HIV/hepatitis C-coinfected patients initiating HAART versus HIV-monoinfected patients initiating HAART.

  • Daniel Fierer, M.D.
    Daniel Fierer, M.D.
    Rapid Liver Fibrosis Occurring More Frequently Among HIV-Infected Men Newly Coinfected With Hepatitis C
    An interview with Daniel Fierer, M.D.

  • Megan Crane
    Megan Crane
    Immune Reconstitution May Trigger Hepatic Flares in HIV/Hepatitis B Coinfected Patients Starting HAART
    An interview with Megan Crane

  • Lars Peters, M.D.
    Lars Peters, M.D.
    HIV/Hepatitis C Coinfection Does Not Influence CD4+ Cell Recovery in Patients on Suppressive HAART
    Lars Peters, M.D., discusses his study, which counters long-established assumptions about the effect of HCV/HIV coinfection on immune recovery after patients commence antiretroviral therapy.

HIV in the Developing World

  • Rebecca Bunnell, Sc.D.
    Rebecca Bunnell, Sc.D.
    HAART Use Enlivens Sex Lives of Rural Ugandans, but Does Not Increase Risky Behavior, Study Says
    A study summary by Rebecca Bunnell, Sc.D.

  • Maria Wawer, M.D.,
    Maria Wawer, M.D.
    HIV Prevention in the Developing World
    Expert panel previews CROI 2008 research.

HIV and Pregnancy

  • Usha Phillips, M.D.
    Usha Phillips, M.D.
    Perinatally Infected Women Experience Viral Load Increase During Pregnancy and Postpartum Period
    Usha Phillips, M.D., discusses her study comparing HIV-infected pregnant women who were perinatally infected versus horizontally infected. Sustained virologic suppression was rarely achieved among the perinatally infected mothers, which may have negative long-term consequences for both the mother and child.

HIV Prevention

HIV Treatment Strategies

  • Cal Cohen, M.D., M.S.
    Cal Cohen, M.D., M.S.
    Management of Treatment-Experienced Patients: A Summary of Key Research
    In this summary and accompanying slide set, Cal Cohen, M.D., M.S., reviews the latest data on new and developing antiretrovirals for HIV drug-resistant patients, including the CCR5 antagonists vicriviroc and maraviroc (Selzentry, Celsentri); the integrase inhibitor raltegravir (MK-0518, Isentress); the NNRTI etravirine (TMC125, Intelence); and the protease inhibitor darunavir (TMC114, Prezista).

  • David Wohl, M.D.
    David Wohl, M.D.
    First-Line HIV Therapy and Treatment Strategies: A Summary of Key Research
    In this summary and accompanying slide set, David Wohl, M.D., examines studies investigating the efficacy of atazanavir (Reyataz) and maraviroc (Selzentry, Celsentri) in first-line use; a comparison between abacavir/lamivudine (Epzicom, Kivexa) and tenofovir/emtricitabine (Truvada); data from ACTG 5142 indicating that race and gender can impact treatment success; and sobering new lessons learned from the pivotal SMART study on CD4-guided HIV treatment interruptions.

  • Atazanavir Noninferior to Lopinavir in Treatment-Naive HIV-Infected People
    Although atazanavir (ATV, Reyataz) is not uncommonly used in first-line patients, it is not officially approved by the U.S. Food and Drug Administration for such use. In a large study presented at CROI 2008, atazanavir + ritonavir (RTV, Norvir) was compared with lopinavir/ritonavir (LPV/r, Kaletra). Dr. Donnie McGrath, of Bristol-Myers Squibb, summarizes the findings.

  • Wafaa El-Sadr, M.D.
    Wafaa El-Sadr, M.D.
    SMART Study Final Results
    Wafaa El-Sadr, M.D., previews the data.

  • Stem Cells: Progress Towards "the Cure"? (April 2008)
    In Project Inform Perspective, from Project Inform
  • Update From CROI 2008 on Approved HIV Drugs (April 2008)
    In Project Inform Perspective, from Project Inform
  • Update From CROI 2008 on Experimental Drugs (April 2008)
    In Project Inform Perspective, from Project Inform
  • Nano Comes to HIV (April 2008)
    In Project Inform Perspective, from Project Inform

Immune-Based Therapies

  • Brian Porter, M.D., Ph.D., M.P.H.
    Brian Porter, M.D., Ph.D., M.P.H.
    Interleukin-2 Ineffective in Maintaining Baseline CD4+ Cell Count During Treatment Interruption
    Brian Porter, M.D., Ph.D., M.P.H., speaks with Gerald Pierone, M.D., about his study of interleukin-2 use during treatment interruption versus interleukin-2 use during continuous HAART.

Pre-Conference News


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.